| Background: Asthma is a heterogeneous disease of airway inflammation,involving a variety of inflammatory cells and cellular components,characterized by airway inflammation and airway hyperresponsiveness.Asthma small airway and atmospheric airway have similar inflammatory response,even more severe inflammation of small airway.Small airway inflammation is positively correlated with the severity of the disease,which can cause high airway response and thickening of the tube wall,etc.,which are the pathological basis and main characteristics of asthma.Clinically,asthma is often monitored by pulmonary function indicators such as forced expiratory volmeinone inone second(FEV1)and peak expiratory flow(PEF).Maintenance therapy of asthma mainly involves Inhaled corticosteroids(ICS)and long-acting 2 receptor agonist(LABA).Routine pulmonary function examinations of PEF and FEVI mainly reflect the function of atmospheric tract,but cannot detect the small airway part with severe inflammatory reaction of asthma,and the evaluation of asthma is insufficient.Common ICS/LABA compound drugs are difficult to fully reach the small airway and inhibit small airway inflammation due to the large diameter of drug particles.Conventional lung function assessment technology and common ICS/LABA combined preparation cannot fully evaluate and treat small airway,so small airway inflammation cannot be effectively suppressed,affecting the efficacy of asthma.The biggest characteristic of beclomethasone/formolol aerosol is the distribution of ultra-fine particles,whose particle size is about half that of ordinary ICS/LABA,which can reach the peripheral small airway more fully and run through the whole bronchial book to achieve the effect of anti-inflammatory and bronchiectasis.FEF50 %,FEF75 % and MMEF(FEF25%-75%)are evaluation indexes of small airway function.Objective:To observe the clinical efficacy and small airway function of beclomethasone/formoterol aerosol(commercial name Foster,100ug/6ug/120)and budesonide/formoterol powder inhaler(commercial name Symbicort Turbuhaler,160g/4.5ug/60)for the treatment of moderate adult bronchial asthma.Methods:Sixty patients with moderate asthma were selected as subjects.The random number table method was used to divide the patients into two groups,30 cases in the observation groupand 30 cases in the control group.30 cases in observation group were treated with inhaled Foster(beclometasone dipropionate and formoterol inhalation aerosol)100ug/6ug,and inhaled once a day in the morning and evening.30 cases in control group were treated with inhaled Symbicort turbuhaler(budesonide and formoterol fumarate powder for inhalation)160ug/4.5ug,and inhaled once a day in the morning and evening.Both groups were received a treatment course of 12 weeks.When the control is not good,Salbutamol sulfate aerosol can be given as needed to relieve clinical discomfort.The change of FEF50%、FEF75%、FEF25%-75% and ACT score between the two groups were before and after 1、2、and 3 months treatment.Result:1.The observation group and control group in 1,2,3 months after treatment,FEF75% 、FEF50 %,、MMEF(FEF25%-75%)small airway function index was increased,the difference was statistically significant(P< 0.05),and the observation group in 1,2,3 months after treatment,FEF75 %、FEF50 % 、MMEF(FEF25%-75%)compared with control group,the difference was statistically significant(P< 0.05).2.The ACT scores of the observation group and the control group were all improved1,2,and 3 months after treatment,with statistically significant differences(P< 0.05),and the ACT scores of the observation group were significantly different from those of the control group at 1,2,and 3 months after treatment(P< 0.05).3.The clinical basic control rates of the observation group and the control group were significantly higher 1,2 and 3 months after treatment than before treatment(P<0.05),and the clinical basic control rates of the observation group were significantly higher 1,2 and 3 months after treatment than the control group(P< 0.05).Conclusion:Beclomethasone and formoterol aerosol for inhalation can improve the function of small airway more effectively,control the clinical symptoms and improve the basic clinical control rate.The treatment of bronchial asthma has more obvious efficacy and has a high clinical value. |
PDF Full Text Request